Monographie - Granisetron hydrochloride

Ultimo aggiornamento :
19/11/2024

Granisetron hydrochloride

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axigran	Arabia Saudita, Germania
Cadigran	India
Cetrexon	Colombia
Em Ex	Egitto
Emegran	India
Emetril	Turchia
Grandem	India
Granic	Iran
Granicip	India
Graniset	India
Granisetrom	Portogallo
Granisetron	Arabia Saudita, Belgio, Canada, Chile, Ecuador, Egitto, Gran Bretagna, Messico, Perù, Romania, Spagna, Stati Uniti d’America, Svezia
Granitero	Portogallo
Granitron	Austria
Granon	India
Granytril	India
Gratil	Iran
Gratryl	Turchia
Helminar	Perù
Kevatril	Germania
Kytril	Arabia Saudita, Australia, Austria, Belgio, Brasile, Chile, Colombia, Danimarca, Ecuador, Egitto, Emirati Arabi Uniti, Finlandia, Germania, Giappone, Gran Bretagna, Grecia, Iran, Irlanda, Italia, Lussemburgo, Malaysia, Marocco, Messico, Paesi Bassi, Perù, Polonia, Portogallo, Spagna, Svezia, Svizzera, Tunisia, Turchia, Ungheria, Venezuela
Manotrox	Messico
Neoset	Turchia
Ribosetron	Germania
Rubrum	Venezuela
Suliftop	Perù
Synarex	Turchia
Tentratec	Messico
Tigron	Turchia
Travigan	Messico
Trilemes	Messico
Vitasetron	Turchia

Bibliografia : Granisetron hydrochloride

	tipo	pubblicazione
6	Rivista	Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm 1994 ; 51: 2138-2142.
27	Rivista	Chin A, Moon YSK, Chung KC, Gill MA. Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days. Am J Health-Syst Pharm 1996 ; 53: 1174-1176.
29	Rivista	Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C. Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. J Pharm Sci 1995 ; 84: 267-268.
48	Rivista	Quercia RA, Zhang J, Fau C, Chow MSS. Stability of granisetron hydrochloride in polypropylene syringes. Am J Health-Syst Pharm 1996 ; 53: 2744-2746.
49	Rivista	Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm 1995 ; 52: 208.
51	Rivista	Chung KC, Chin A, Gill MA. Stability of granisetron hydrochloride in a disposable elastomeric infusion device. Am J Health-Syst Pharm 1995 ; 52: 1541-1543.
57	Rivista	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
182	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
249	Rivista	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Rivista	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Rivista	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
921	Rivista	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Rivista	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410	Rivista	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Rivista	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Rivista	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Rivista	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Rivista	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1633	Rivista	Walker SE, Law S. Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions. Can J Hosp Pharm 2002 ; 55: 27-38.
1662	Rivista	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1676	Rivista	Hourcade F, Sautou-Miranda V, Normand B, Laugier M, Picq F, Chopineau J. Compatibility of granisetron towards glass and plastics and its stability under various storage conditions. Int J Pharm 1997 ; 154: 95-102.
1712	Rivista	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1721	Rivista	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Rivista	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Rivista	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Rivista	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Rivista	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2262	Rivista	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Rivista	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335	Rivista	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3249	Rivista	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3459	Rivista	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3571	Rivista	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3805	Rivista	Chen F.C, Xiong H, Liu H.M, Fang B.X, Li P. Compatibility of butorphanol with granisetron in 0.9% sodium chloride injection packaged in glass bottles or polyolefin bags. Am J Health-Syst Pharm 2015 ; 72:1374-1378.
3824	Rivista	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	Rivista	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4061	Rivista	Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous granisetron hydrochloride. Int J Pharm Compound 2018 ; 22,1 :86-94
4116	Rivista	Chen F, Zhu J, Li B, Yuan F, Wang K. Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems. Drug Design Dev Ther 2016 ;10:1869-1875
4310	Rivista	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
4319	Rivista	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4429	Rivista	Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H. Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. Medicine 2016 ; 95:25(e3824)
4603	Rivista	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Rivista	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales